AALL1131Blinatumomab in First Relapse of B Lineage Acute Lymphoblastic Leukemia

When:  Oct 12, 2017 from 1:00 PM to 2:00 PM (CT)

Thursday, October 12, 1:00pm CT


AALL1331Blinatumomab in First Relapse of B Lineage Acute Lymphoblastic Leukemia

Sue Zupanec, RN

Hospital for Sick Children

Debra Schissel, RN CPON®

Children’s Hospital Colorado


 Current survival rates for most pediatric patients with a first relapse of acute lymphoblastic leukemia (ALL) are dismal. Treatment strategies for relapsed ALL include intensive chemotherapy often followed by hematopoietic stem cell transplant. Blinatumomab is a new targeted therapy that has shown promising clinical activity in early phase clinical trials in both adult and pediatric patients with relapsed ALL. Blinatumomab is a bispecific T-cell engager linking CD19 positive B-cells, including ALL cells, with CD3 T-cells, inducing T-cell activation and apoptosis. Blinatumomab has a distinctive toxicity profile including cytokine release syndrome (CRS) and reversible neurotoxicity.  The current COG AALL1331 study aims to determine if the addition of Blinatumomab will improve outcomes for pediatric patients with a first relapse of ALL.  This session will review the COG AALL1331 protocol and will include discussion of Blinatumomab administration and highlight nursing care of patients enrolled on this trial.

Learning Objectives:       

 Review the background of pediatric relapsed ALL, including, risk classification, survival rates, and the most promising clinical trial results to date.

  1. Describe the mechanism of action of Blinatumomab and review clinical activity and reported toxicity from early phase clinical trials both in adult and pediatric patients.
  2. Review the COG AALL1331 protocol and the nursing considerations important for Blinatumomab administration and for the provision of nursing care for patients receiving this new targeted agent.

 Identified Learning Gap: 

 As a result of attending this activity, the learner will be able to demonstrate an increase knowledge base in:

  • New and innovative therapies in hematology, oncology and hematopoietic progenitor cell transplant.
  • Current trends in hematology/oncology and hematopoietic progenitor cell transplant.
  • Pharmacotherapy


Learning Outcomes:


Learning Outcome 1: 
The learner will be able to identify innovative strategies essential for managing the challenges facing pediatric hematology/oncology nurses and the patients we serve.


Learning Outcome 2: 
The learner will demonstrate increased knowledge related to the care of children, adolescents and young adults with hematologic or oncologic disorders.


The measurement of these outcomes will be evidenced by evaluations and post testing.


APHON members may earn CNE at no cost, the fee for non-members is $15. Participants will be awarded 1 CNE contact hour upon completion of the hour-long webinar and completion of a post-test and evaluation. Attendance for the entire webinar session is required for CNE credit. A link to complete the evaluation form and claim CNE contact hours will be distributed after each webinar.


The Association of Pediatric Hematology/Oncology Nurses (APHON) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Faculty Disclosure of Relevant Financial Relationship(s): Faculty and nurse planners report no conflict of interest with the content of this activity.


Registration Now Open


<strong>Dial-in Instructions: </strong>


Jennifer Schap